The very discussion of chloroquine and hydroxychloroquine as therapeutic options against COVID-19 has decreased their availability for proven treatments, exacerbated global shortages, fueled an already rampant counterfeit drug market in Africa, and worsened trade tensions. Student Sangita Baxi (cohort '17) and professors Krishna Kumar and Todd Richmond ask, What can be done to deal with the unintended consequences caused by the elevated profile of these drugs?
